奥沙利铂联合S-1胶囊方案和FOLFOX6方案治疗晚期胃癌的疗效观察

目的观察奥沙利铂联合S-1胶囊（替吉奥胶囊）方案和FOLFOX6方案治疗晚期胃癌的临床疗效、毒副反应及生存期。方法将2009年1月～2012年6月在我院肿瘤内科治疗的118例晚期胃癌患者作为研究对象，随机分为治疗组（奥沙利铂联合S-1胶囊方案）60例和对照组（FOLFOX6方案）58例。两组患者化疗均不少于三周期后才进行近期疗效、毒副反应及生存期等比较。结果治疗组60例，总有效率为55．0％，对照组总有效率为32．8％，两组比较，差异有统计学意义（P＜O．05）；但两组患者初治有效率（42．3％VS66．7％）与复治有效率（25．0％VS45．5％）比较，差异无统计学意义（均P〉0．05）。两种方案毒副反应均较轻，以骨髓抑制及消化系统反应为主，对照组恶心呕吐发生率明显高于治疗组，差异有统计学意义（P＜0．05）。结论奥沙利铂联合S-1胶囊方案与FOLFOX6方案在晚期胃癌治疗上都有一定疗效，且化疗的毒副反应能被患者耐受。但奥沙利铂联合S-1胶囊方案的临床疗效更高．消化道毒副反应轻微，更容易被患者接受，值得临床广泛运用。

Curative effect of oxaliplatin combined with S 1 capsule scheme and FOLFOX6 scheme on treatment of advanced gastric cancer

Objective To observe the curative effectof oxaliplatin combined with S 1 capsule scheme and FOLFOX6 scheme on treatment of advanced gastric cancer. Methods 118 patients with advanced gastric cancer were randomly di- vided into treatment group （oxaliplatin and S 1 capsule scheme, 60 cases） and the control group （FOLFOX6 scheme, 58 cases）. The recent curative effect, adverse reaction and survival were observed, Results The total effective rate of treatment group and control group were 55.0% and 32.8%（P〈0. 05）. There no statistically significant difference of initial treatment efficiency and retreatment efficiency between the two groups. The adverse reaction was light includeing bone marrow suppression and digestive system reactions. Conclusion Oxaliplatin combined with S 1 capsule scheme and FOL- FOX6 scheme in treatment of advanced gastric cancer has eertain curative effect, and the side reaction of chemotherapy can be tolerance.